Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInvested CapitalMarket CapitalizationNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Keros Therapeutics (KROS) Asset Utilization Ratio: 2020-2025

Historic Asset Utilization Ratio for Keros Therapeutics (KROS) over the last 4 years, with Sep 2025 value amounting to 0.33.

  • Keros Therapeutics' Asset Utilization Ratio rose 26032.88% to 0.33 in Q3 2025 from the same period last year, while for Sep 2025 it was 0.33, marking a year-over-year increase of 26032.88%. This contributed to the annual value of 0.01 for FY2024, which is 1513.90% up from last year.
  • Keros Therapeutics' Asset Utilization Ratio amounted to 0.33 in Q3 2025, which was up 8.91% from 0.30 recorded in Q2 2025.
  • Keros Therapeutics' Asset Utilization Ratio's 5-year high stood at 0.33 during Q3 2025, with a 5-year trough of -0.00 in Q2 2021.
  • For the 3-year period, Keros Therapeutics' Asset Utilization Ratio averaged around 0.13, with its median value being 0.11 (2023).
  • As far as peak fluctuations go, Keros Therapeutics' Asset Utilization Ratio crashed by 100.10% in 2021, and later surged by 817,057.81% in 2022.
  • Keros Therapeutics' Asset Utilization Ratio (Quarterly) stood at 0.08 in 2021, then soared by 817,057.81% to 0.15 in 2022, then reached 0.11 in 2023, then tumbled by 94.58% to 0.01 in 2024, then soared by 26,032.88% to 0.33 in 2025.
  • Its Asset Utilization Ratio was 0.33 in Q3 2025, compared to 0.30 in Q2 2025 and 0.31 in Q1 2025.